Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 67

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 67
---
ownership limitation described above, such securities or property that such holder could have acquired if such holder had held the number
of Depositary Shares issuable upon complete exercise of the February Placement Agent Warrant immediately prior to the date a record is
taken for such issuance. If we declare or make any dividend or other distribution of assets or rights to acquire assets to holders of
Depositary Shares or Ordinary Shares, a holder of a February Placement Agent Warrant will be entitled to participate, subject to the beneficial
ownership limitation, in such distribution to the same extent that the holder would have participated therein if the holder had held the
number of Depositary Shares issuable upon full exercise of the February Placement Agent Warrant.

| 41 |

Fundamental Transaction.If we effect a fundamental transaction, including, among other things, a merger, sale of substantially all of our assets, tender offer,
exchange offer and other business combination transactions, then upon any subsequent exercise of a February Placement Agent Warrant, the
holder thereof shall have the right to receive, for each Ordinary Share represented by the Depositary Shares that would have been issuable
upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of the successor’s
or acquiring corporation’s securities, if it is the surviving corporation, and any additional consideration receivable as a result
of such fundamental transaction by a holder of the number of Ordinary Shares represented by the Depositary Shares for which the February
Placement Agent Warrant is exercisable immediately prior to such fundamental transaction. In addition, in the event of a fundamental transaction
that is (i) an all cash or substantially all cash transaction, (ii) a “Rule 13e-3 transaction” as defined in Rule 13e-3 under
the Exchange Act, or (iii) with certain limited exceptions, a fundamental transaction involving a person or entity not traded on a national
securities exchange or other established trading market, including, but not limited to, the London Stock Exchange, AIM, The New York Stock
Exchange, Inc., The NYSE MKT, The NASDAQ Global Select Market, The NASDAQ Global Market, The NASDAQ Capital Market, the OTC QX, the OTC
QB or the Over-the-Counter Bulletin Board, then the Company or any successor entity will pay at the holder’s option, exercisable
at any time concurrently with or within 30 days after the consummation of the fundamental transaction, an amount of cash equal to the
value of the February